Saturday 17 October 2026 Export PTN’s income statement to Excel — free account

Palatin Technologies, Inc.

In the quarter to June 2026, revenue fell 14.1%, EPS fell 276.3% and free cash flow grew 34.2%, each against the same quarter a year earlier.

6.02 0.47 −7.24%

Follow PTN

Alert me

Market cap: $11.6M
P/E: 0.0×
Fwd P/E: 0.2×
Dividend yield: —
F-score: n/a
Altman Z: −67.72
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.01

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	1	—	—	—	—	—	—	—	—	—	—

Insider Ownership 40.57%

Capital & Financial Ratios $m

Market Cap 11.55

Revenue 13.19

Net Income (8.38)

Free Cash Flow (13.59)

Net Debt (7.49)

Current Ratio 4.61

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E 0.16

P/S ratio 1.29

P/B ratio 2.55

Past 5Y EPS Growth —

This Y EPS Growth 26.24%

Next Y EPS Growth 2.60%

Next Y revenue growth (34.65%)

Next 5Y EPS Growth 3.08%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 7.11%

10-year low 10-year high

P/B against its own 10 years 33.30%

10-year low 10-year high

EV/Sales against its own 10 years 11.56%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	11	10	3	7
Receivables	3	—	0	0
Inventory	1	—	—	—
Other	—	—	—	—
	16	10	3	8

	2023	2024	2025	2026
Payables	4	4	7	1
ST’ Debt	—	—	—	—
Other	4	1	—	—
	15	10	8	2

Compound Annual Growth %

	10y	5y	3y
Sales	50.83%	156.83%	107.84%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(33.03%)	0.00%

Revenue $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	9	0	4	0	13
’24	2	2	—	0	4
’23	1	1	1	2	5
’22	0	0	0	1	1
’21	0	0	0	0	0
’20	0	0	—	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(2)	(5)	(4)	(3)	(14)
’25	(7)	(5)	(5)	(4)	(21)
’24	(6)	(10)	(9)	(6)	(31)
’23	(9)	(10)	(1)	(10)	(29)
’22	(6)	(6)	(9)	(8)	(30)
’21	4	(14)	(4)	(9)	(23)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(2)	(5)	(4)	(3)	(14)
’25	(7)	(5)	(5)	(4)	(21)
’24	(6)	(11)	(9)	(6)	(32)
’23	(9)	(10)	(2)	(10)	(30)
’22	(6)	(6)	(10)	(8)	(30)
’21	4	(14)	(4)	(9)	(23)

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	4.26	(2.86)	(0.37)	(4.00)	(2.96)
’25	(19.50)	(6.00)	(9.00)	2.58	(32.17)
’24	(24.00)	(28.00)	(26.50)	(25.50)	(101.00)
’23	(43.00)	12.53	(31.50)	(45.50)	(126.50)
’22	(37.50)	(50.00)	(37.50)	(67.00)	(189.50)
’21	(25.00)	(50.00)	(25.00)	(75.00)	(175.00)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	362.50	737.50	825.00	450.00	412.50	107.00	71.50	34.00	2.00	6.00	Analyst estimates 2027–2029 Powerpack
	High	1,312.50	1,987.50	2,225.00	1,125.00	1,625.00	687.50	250.00	282.50	72.50	24.49
People
People	Employees	22	19	18	20	26	33	34	30	29	25
	Revenue/emp, $m	2.03	3.53	3.35	0.01	(0.01)	0.04	0.14	0.15	0.00	0.53
Income, $m
Income, $m	Revenue	45	67	60	0	0	1	5	4	—	13
	Gross margin, %	100.00	100.00	100.00	100.00	178.37	85.18	91.38	97.83	—	100.00
	EBT	(13)	25	36	(22)	(34)	(36)	(29)	(30)	(17)	(8)
	EBT margin, %	(28.69)	36.92	59.32	(19,005.08)	17,813.63	(2,464.98)	(591.54)	(662.26)	0.00	(63.54)
	Net income	(13)	25	36	(22)	(34)	(36)	(24)	(30)	(17)	(8)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	303.62	423.56	363.04	0.63	(1.00)	7.69	22.29	15.27	0.00	4.66
	Earnings	(87.50)	150.00	212.50	(125.00)	(175.00)	(189.50)	(126.50)	(101.00)	(28.86)	(2.96)
	Cash flow	87.45	10.75	(131.14)	220.17	(119.64)	(156.75)	(134.40)	(107.01)	(39.60)	(4.79)
	Capex	(0.91)	(0.14)	(0.22)	(0.34)	(0.03)	(1.37)	(1.99)	(0.14)	0.00	(0.02)
	Free cash flow	86.55	10.60	(131.36)	219.84	(119.67)	(158.12)	(136.39)	(107.16)	(39.60)	(4.81)
	Book value	(35.06)	170.13	605.35	427.13	262.29	85.22	(9.09)	(0.38)	(8.88)	2.37
	Shares, m	0	0	0	0	0	0	0	0	1	3
Valuation, ×
Valuation, ×	P/E	0.00	8.06	6.41	0.00	0.00	0.00	0.00	0.00	—	0.00
	P/S	1.37	2.89	2.52	1.99	0.00	45.50	4.71	4.37	—	2.31
	P/B	0.00	7.20	2.25	1.50	2.91	4.11	0.00	0.00	—	4.56
	EV/Sales	0.78	2.33	2.04	0.64	(453.04)	25.54	2.48	2.87	—	1.75
	EV/FCF	3.53	93.12	(8.39)	0.93	(3.77)	(1.24)	(0.41)	(0.57)	—	(1.70)
Cash, $m
Cash, $m	Operating cash flow	13	2	(22)	41	(23)	(30)	(29)	(31)	(21)	(14)
	Capex	0	0	0	0	0	0	0	0	—	0
	Free cash flow	13	2	(22)	41	(23)	(30)	(30)	(32)	(21)	(14)
Balance, $m
Balance, $m	Working capital	2	28	100	80	55	18	1	0	(5)	6
	Total debt	6	0	0	1	1	0	0	—	—	—
	Net debt	(34)	(38)	(44)	(82)	(59)	(30)	(11)	(10)	(3)	(7)
	Shareholders’ equity	(5)	27	101	80	50	16	(2)	0	(5)	7
Returns, %
Returns, %	ROA	(39.39)	51.54	49.77	(23.63)	(44.10)	(70.04)	(89.01)	(207.35)	(247.08)	(142.11)
	ROIC	0.00	0.00	39.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	117.20	226.63	56.11	(24.82)	(51.76)	(109.83)	(336.46)	2,843.65	708.07	(877.59)

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2026 · fundamentals updated 30 Sep 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ASBP Aspire-Lakewood Holdings, Inc.	$12.1M	0.2×	—	—	n/m	−85.54% (below 0%: shrinking)	(47.70%)	(4,244.37%)	Compare
ACTU Actuate Therapeutics, Inc.	$12.0M	— (loss-making)	—	—	n/m	−5.54% (below 0%: shrinking)	—	0.00%	Compare
PLUR Pluri Inc.	$11.9M	— (loss-making)	— (loss-making)	−15.83% (below 0%: shrinking)	n/m	+25.03% (above 0%: growing)	58.51%	(1,655.52%)	Compare
INAB IN8bio, Inc.	$11.7M	— (loss-making)	—	—	n/m	−1.30% (below 0%: shrinking)	0.00%	0.00%	Compare
ENSC Ensysce Biosciences, Inc.	$11.6M	— (loss-making)	— (loss-making)	−15.10% (below 0%: shrinking)	n/m	+27.50% (above 0%: growing)	100.00%	(221.28%)	Compare
PASG Passage Bio, Inc.	$11.6M	— (loss-making)	—	—	n/m	−59.81% (below 0%: shrinking)	0.00%	0.00%	Compare
PTN Palatin Technologies, Inc.	$11.6M	— (loss-making)	0.2×	−14.06% (below 0%: shrinking)	n/m	+34.21% (above 0%: growing)	100.00%	(1,469.35%)
CLRB Cellectar Biosciences, Inc.	$11.2M	— (loss-making)	—	−73.23% (below 0%: shrinking)	n/m	−17.49% (below 0%: shrinking)	0.00%	0.00%	Compare
INTS Intensity Therapeutics Inc.	$11.0M	— (loss-making)	—	—	n/m	+4.72% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$11.7M	—	—	−15.83%	—	−3.42%	0.00%	0.00%

All 614 Biotechnology stocks →

Palatin Technologies, Inc. (PTN) key facts

Palatin Technologies, Inc. (PTN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PTN traded at $6.02, a market capitalization of $11.6 million.
Return on equity was −877.6% and debt-to-equity 0.00.
Its Altman Z-score is −67.72 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Sep 30, 2026.